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2. The objectives of this study were.
 
ra a) Using a bedrest model to determine the role of the renin-angio­
0 I4, 
P-1 tensin-aldosterone system in the cardiovascular deconditioning of 
OnO space flight and in the severe electrolyte disorders seen with pro-
M M ,4 4-)' longed weightlessness.­
.v4 Q)1H (1 b) To determine if the cardiovascular deconditioning and electro­)) 

V4H 0 $4 VCD i CZ (ilyte be prevented, abnormalities associated with space flight can 

Min V ( by pharmacologic interventions involving the renin-angiotensin-aldos­
2E; Nterone system.
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P4 .4 Because of unanticipated scheduling delays at the N.A.S.A. bedrest 
'H P1E-40CAPC facility, itwas not possible to begin clinical studies during the
 
04 AC40 
- W;V W1first year of this project. During the project period some modifications 
were introduced into the protocol in order to incorporate non-invasive 
techniques of assessing'cardiac function (echocardiography) and arrange­
\Q/Q.-,- F ments were made with the Squibb Company to make available the orally 
P _, ctive dipeptide converting-enzyme inhibitor for bedrest studies. How­
zrever, during the delay in the initiation of clinical studies, we elected 
https://ntrs.nasa.gov/search.jsp?R=19780014762 2020-03-22T04:51:26+00:00Z
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to investigate two aspects of the proposed study inorder to gain new
 
insights into the mechanism of the electrolyte abnormalities of spaceflight.
 
a) Spaceflight and prolonged bedrest are associated with naturesis and
 
kaliuresis; any attempt to explain or present this abnormality in electrolyte
 
metabolism must take into consideration all factors known to infl'uence
 
naturesis. Recently, a role for the pituitary hormone prolactin in the
 
regulation of electrolyte excretion and its control of aldosterone has
 
been suggested (1-7). While some opposing data are available (8-10) to
 
demonstrate that acute endogenous hyperprolactinemia does not alter electro­
lyte metabolism, the issue remained unresolved. Because of the possibility
 
that hyperprolactinemia might play a role in the hyperaldosteronism of bedrest
 
and spaceflight, we investigated the effect of endogenously-produced hyper­
prolactinemia on the secretion of aldosterone. Thyrotropin releasing hormone
 
(TRH), a known secretogogue of pituitary prolactin, was administered to normal
 
female subjects to induce endogenous hyperprolactinemia. No elevation in
 
plasma aldosterone was seen for one hour following the induction of hyper­
prolactinemia. Because prehypothyroid women respond to thyrotropin releasing
 
hormone with an exaggerated prolactin response, we administered TRH to a
 
group of these women and followed serum aldosterone concentrations. In spite
 
of hyperprolactinemia no stimulation of aldosterone was observed. Finally
 
a group of patients with pituitary tumors and extremely high serum prolactin
 
concentrations were studied and no evidence for hypersecretion of aldosterone
 
was,detected. The details of these studies are included in the accompanying
 
manuscript (in press, Clinical Endocrinology). Thus, it does not appear that
 
endogenous hyperprolactinemia plays an important role in the control of
 
aldosterone secretion and this observation taken together with previously
 
published data (8-10) make it unnecessary to explicitly investigate the
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possible role of prolactin in the naturesis of spaceflight.
 
b) Prolonged inhibition of converting-enzyme by either the continuous
 
administration of nonapeptide or dipeptide (oral) converting-enzyme in­
hibitor will play a role in our proposed studies of bedrest and spaceflight.
 
While awaiting availability of space at the N.A.S.A. bedrest facility, we
 
undertook to begin an investigation of the effects of prolonged administration
 
of nonapeptide inhibitor to man (Re, Escourrou, Talamo, and Haber - manuscript
 
in preparation). A 28-year old, severely hypertensive male was studied on the
 
metabolic ward of the Massachusetts General Hospital after wi-thdrawal of
 
antihypertensive medication. Nonapeptide converting-enzyme inhibitor was
 
administered intravenously on an intermittent basis as needed for blood
 
pressure control over a three-day period- Diastolic blood pressure, al­
though not normalized, was consistently reduced by 30mm Hg. The patient
 
suffered no ill effects from his therapy. Following the initial injections
 
of CEI, plasma renin increased (from about 2.0 ng/ml/hr to 12.0 ng/ml/hr),
 
but by the end of the therapy period no'such brisk response occurred, sug­
gesting possible "exhaustion" of renin release. No tachyphylaxis secondary
 
to hyperreninemia was observed. Plasma bradykinin was determined before
 
and after CEI administration (doses of CEI ranged from 0.25 mg/kg to I mg/kg).
 
No increase i'n bradykinin was observed (values were 0.25 ng/ml before CEI
 
and <0.35 ng/ml following most injections of CE). Thus, CEI can produce
 
inhibi'tion of converting enzyme and lowering of blood pressure without hyper­
bradykininemia, thus pointing out that CE-I is potentially a "cleaner" block­
ing agent than previously thought (11). Significant naturesis was not consis­
tently observed in this patient, but it must be remembered that this patient
 
was not continuously infused with the drug.
 
-4-
Thus, this study provided considerable insight into the effects of long­
term CEI administration in man and provides the background for future
 
continuous infusion experiments.
 
Along with the above study, we undertook the perfection of a radio­
immunoassay for angiotensin Ii and the development of new antisera for the
 
accurate measurements of this compound. We now have a working radioimmuno­
assay with detection limit of about 12 pg/ml and we are continuing develop­
ment of newer assays. This is important to the monitoring of Angiotensin II
 
levels in clinical studies of spaceflight, especially (though not exclusively)
 
those involved with the administration of CEI.
 
Thus, we have made considerable progress in the last year, and it is
 
clear that the next reasonable step in our research would be a study of
 
continuous CEI administration to normal volunteers in order to assess its
 
effects on renal function. This could be done at the M.G.H. and would not
 
require use of the N.A.S.A. bedrest facility.
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SU IMARY 
It has been suggested that prolactin is a regulator of aldosterone secre­
tion. In order to test this hypothesis, we measured prolactin, thyrotropin 
and aldosterone by radiommunoassay and plasma renin activity by the radio­
immunoassay of angiotensin I in 8 normal women before and after the intravenous 
injection of 200 pg of thyrotropin releasink hormone. Prolactin increased from
 
4.4 + 1.1 ng/ml (mean + SE) to a peak of 27.4 + 3.8 (p < 0.005) at 15 minutes 
following thyrotropin releasing hormone. Plasma renin activity was not 
different from control levels (1.0 + 0.2 ng/ml/hr) during t-he first hour
 
following the administration of thyrotropin releasing hornone, nor did the
 
plasma aldosterone concentration differ significantly from the control 
levels (39 + 7 pg/ml) during this period. 'However, with upright 
posture, an increase in aldosterone (from 31 + 3 pg/ml at 1 hr to 68 + 9 at 
2 his, p < 0.005)' and in plasma renin activity (from 0.9 _- 0.2 ng/ml/hr at 
1 hr to 2.0 + 0.5 at 2 hrs, p < 0.05) wias noted, demonstrating a normal 
capacity to secrete aldosterone in these subjects.
 
Similarly, no change in al{losterone was seen in 9 patients with primary
 
hypothyroidism given thyrotropin releasing hormone, despLtC the fact 'that
 
the increase in prolactin was greater than normal. Chronic hyperprolactinemia
 
was not associated with hyperaldosteronism in 6 patients wilth pituitary
 
tumor. These data demonstrate that acutely or chronically elevated serum
 
prolactin levels -o not result in increased plasma aldosterone levels in
 
humans. 
I NI RODUC ION 
Prolactin has been demonstrated to have a qod unm retaining action in 
marine teleosts, and there are data to suggest lhat in mnamals it also plays 
a role in sodium homeoStasLS and osmoregnlaLion (Locket & Nail, 1965; Locket, 
1965; llorrobLn etcal., 1973, Relkin & Ndachi, 1973; Buckman & Peake, 1973, 
Buckman et A., 1976, Horrobin et al., 1971). Recently attention has been 
focused on the possibility that prolactin stimulates secretion of aldosterone 
by the adrenal cortex (Beck et al., 1964; Horrobin, 1975; Edwards et Ki., 
1975). Baumann and Loriaux (1976), however, have reported that elevations 
in endogenous prolactin in normal men induced by thyrotropLn releasing
 
hormone were not associated with increased plasma aldosterone, cortisol, or
 
renal electrolyte excretion, and similar results were obtained by Ogibara
 
et al., 1977, using metoclopramide to stLmulate prolactin secretion in 
normal men.
 
We have xnvestLgaLed the effect of elevations in serum prolacLin induced 
by thyrotropin releasing hormone on the control of aldosterone secretion in 
normal women and in women with primary hypothyroidi&m, uhose thyrotropin 
releasing hormone-stimulated prolactin levels are supranormal. We have also studied 
levels in patients with a pituitarythe effect of chronically elevated prolactin 
tumor. 
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Sub lecL: Light normal women (euthyroLd with normal menstrual cycles 
and on no medications) between 21 and 29 years of age were injected with 
200 vg of thyrotroptn ieleasing hormone intravenously at 8 A.I1. while supine. 
Patients remained Supine for one hour and engaged in ad i ibvtit activity 
thereafter. Blood was obtained at various time intervals before and for 
three hours after thyrotropin releasing hormone injection (200 pg i.v.) and 
assayed for aldosterone, plasma renin activity, thyroid stimulating hormone, 
prolactin, thyroxine (T 4), free thyroxine (FT4) and triLodothyronine (T3). 
Similar studies were performed in 9 women (30-56 years old) with 
untreated primary hypothyroidism (including 4 women with galactorrhea), and 
in 4 women and 2 men (25--69 years old) with a proven pituitary tumor and 
chronically elevated prolactan. Clinical information regarding the patients
 
with pituitary tumors is provided in Table I; only one patient with pituitary 
tumor required glucohorticoid replacement. The 2 premenopausal women with a
 
pituitary tumor had ga]actorrhea. All patients were studied on an ad libitum 
diet. 
LaboraLory Studies: Plasma renin activity was measured by the method of 
Haber et al. (1969) (normal < 0.1--4.7 ng/l/hr). Plasma aldosterone was 
determined by a sensttive radioLmmunoassay which does not require preliminary 
chromatography (Poulnen at AZ., 1974) (normal t 15-270 pg/mi). '[hyroLd 
stimulating hormone wos determined by radioimmunoassay (Ridgway at aZ., 1973) 
(normal < 0.5-3.2 llU/m]). ProlacLin was measured by a homolo,ops radioimmu­
noassay (GautvLk et Q., 1974, Kourides et al., 1976) (normal < 2-12 ng/ml). 
T4 (normal = 4-11 vg/dl) and FT4 (normal = 0.8--2.4 ng/dl) were determined
 
by competitive protein binding assay and equilibrium dialysis respectively 
(Ridgway et al , 1973). T3 was determined (normal = 70-1/0 ng/dl) by 
--
rad loimmunoaqay ((autvik c! cZ., 1974). 
Anals1,s of DIca: Data for each group were analyzed by paired Student's 
t-test. Comparisons between groups were performed by Student's t-test or
 
one-way analysis oA variance as appropriate.
 
RIS LI I L S 
Norma LSubi ecLs: Normal subjects had a mean serum '14 of 6.4 - 0.5 vg/dl 
(mean + SE), FT4 of 1 2 + 0.1 ng/dl, T 3 of 81 _F 4 ng/di , and thyroid stimulating 
hormone of 1.6 + 0.3 It/m]. tean prolactin increased from 4.4 + 1.1 ng/ml 
before thyrotropin releasing hormone to a peak of 27 -F 3.8 at 15 minutes 
following thyrotropin releasing hormone (p < 0.005). H1owever, plasma renin 
activity before thyrotropin releasing hormone, 1.0"+ 0.2 ng/ml/hr and maximal 
plasma renin activity during the first hour after thyrotropin releasing 
hormone, 1.0 + 0.3 ng/ml/hr, were not different. SimilarLy, plasma aldosterone
 
before thyrotropin releasing hormone, 39 + 7 pg/mi, and maximal plasma aldos­
terone during the first hour after thyrotropin releasing hormone, 39 + 6 pg/ml
 
(Figure 1) were not different. However, with the assumption of upright posture 
(between hours 1 and 2 of this study) , increases in plasma renin actLivty 
(0.9 + 0.2 ng/ml/hr at one hour, to 2.0 + 0.5 ng/nl/hr at Wo hours, p < 0.05)
 
and in plasma alidosterone (from 31 + 3 pg/mI at one hour to 68 +- 9 at two
 
hours, p < 0.005) were noted, indicating a normal capacity to secrete aldos­
terone 	in these stibjects.
 
Prolactin hyperres|ponders: The 9 patients with primary hypothyroidism
 
had a mean T of 1.4 -_ 0.4 vig/dl, FT1 of 0.3 + 0.1 ng/dl, T_ of 43 + 9 ng/dl,
 
hormone of 119 + 19 11U/ml. Following thyrotropin
and thyrold stimulating 

releasing hormone, prolacLtin increased from a mean of 13 + 1.9 ng/dl to 132
 
4- 12 ng/dl at 15 minutes (p < 0.001) and to 88 ± 17 ng;/di at 60 minutes
 
(p < 0.001). .1he prolactin levels in these patients were stgnfLicantly greater 
than those in the normals at .15 minutes (p < 0.001). Plasma aldosterone was 
49 + 11 pg/ml before thyrotroptn releasing hormone and was not significantly 
pg/ml)increased at 15 minutes (43 + 10 pg/ml) or at 60 minutLes (60 - 13 
(Figure 2). In additLon, when one-way analysis of variance was carried out, 
-6­
there was no significant dtfference among the zcro time, 15 ivtnutc, or 60 
minute aldosterone values. Mean basal aldosterone concentration in the hypo­
thyroid patients was also not significantly different from that of normals.
 
Chronic Prolactin Ilypersecreters: - In the 6 patients with a pituitary 
tumor and chronic hyperprolactinemia, mean serum T4 was 7.3 + 1.9 Rg/di, 
FT4 was 1,9 + 0.6 ng/dl, T3 was 148 + 41 ng/dl, and thyroLd stimulating 
hormone was 3.2 + 2.2 pU/ml. Thyrotropin releasing hormone infusion resulted 
in small increases in prolactin (Table 10 which were not statistically 
significant. Mean basal plasma aldosterone (62 - 18 pg/mi) in these patients 
was not significantly different from that of normals, and no significant' 
increase in plasma aldosterone occurred following thyrotropin releasing hormone.
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DiSUSS [ON 
Prolactni has been demonstrated to play an osmoreuiatorv role in fish 
(Ensor & Ball, 1972). Although the action of this hormone in mammals seems 
predominantly related to breast development, data exist to suggest that Lt 
also plays a role in sodium retention ,nd osmoregulation (Locket & Nall, 1965; 
Locket, 1965; llorrobin et al., 1973; Relkin & Adachi, 1913; Buckman & Peake, 
1973; Buckman et al., 1976; Horrobin et aZ., 1971; Buckman et al., 1973). 
While it has been suggested that prolactin may directly act on the kidney to 
promote sodium reabsorption (Locket, 1965; Horrobin et al., 1971), recent 
studies have focused on the Possibility that prolactin ' imulates adrenal 
secretion of aldosterone. Increased urinary excretion of aldosterone has
 
been reported in man following the administration of ovine prolactin (Beck
 
et a.,, 1964). However, when endogenous pro)actin was trasLently increased 
in normal men by the administration of thyrotropin releasLng horr'one, no 
change in plasma aldosterone or urinary electrolytes IaS found (Baumann & 
Loriaux, 1976). It is possible that vasopresstn contamination of the ovine
 
prolactin used in the earlier studies may account for the reported differ­
ences in electrolyte excretion. A-correlation between the diurnal rhythms 
of aldosterone and prolactin has been reported in man (Ilorrobin, 1975), but 
a recent study falied to demonstrate this correlition in raLs (Gomez-Sanchez 
el al., 1976). Finally, bromergocryptine, an inhibitor of pituitary prolactin 
secretion, has been ',hown to block the normal Inurease, in plasma aldostorone 
.seen following furosemide administration in man, without an tnhibition of 
renin stimulation (Edwards at al., 1975). While a direct suppressive effect 
of bromergocryptine on the secretion of aldosterone by the adrenal (ould not 
be excluded, the data raised the possibility that bromergocryptine-mediated
 
suppression of pituttary prolactin secretion led to the absence of an aldosterone 
response to elevated plasma renin activity. ORIGNAL PAGE 6 
OP DOOR QUALKY 
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We have increased endogenous prolactLn levels in normal, womem by the 
administration of thyrotropin releasing hormone, but no change in plasma 
renin activity or plasma aldosterone followed the increase in prolactin. 
These data concur with those reported mnly Fornormal iten by Baumann & Lortaux 
(1976). In order to determine whether greater elevations in endogenuus 
prolactin might stimulate aldosterone secretion, we extended these investi­
gations by for the first time studying plasma aldosterone concentrations in
 
hypothyroid patients who were prolactin hyperrespohders to thyrotropin
 
releasing hormone. Acute supranormal elevation in prolactin was associated
 
with only a small rise in plasma aldosterone at 60 minutes, uhich was not
 
statistically significant. Additionally, we studied patients with chronically
 
increased prolactin due to pituitary tumor and found their plasma aldosterone
 
to not be significantly dnfferent from that of our 8 norrnal subjects, and 
to be within the normal range for aldosterone in our laboratory. In these 
patients with severe chronic hyperprolactinemia, thyrotrop-n releasing hormone 
infusion -resulted in no change in plasma aldosterone and little further
 
increase in prolactin. Hormonal deficiencies in the piLULtary tumor 
patients were varied, ranging from virtually normal piltuitar function
 
(patient M.H.) to deficiencies of adrenocorticotropLn and thyrotropin 
(patient S.C.). Thus it ns highly unlikely that the deficiency of any 
particular piLtutary hormone masked a stimulatory effect of prolactin on 
aidosterone. It is thus reasonable to infer from absence of hyperaldoster­
onism in our patUntq with pituitary tumor and hyperprol]act nemta that chronic 
elevation of prolactin has little effect on plasma aldosLterone.
 
Our data demonstrate that under the conditions of this study, neither
 
transient nor chronic increases in endogenous prolattin lead to significant 
increases in Vlasma aidosterone. These findings, taken with the demonstration 
ORIGIL PAGE 5 
OF POOR QIJA 
Ilat chronLC Iyjperprol.i( tiiinla (Ios noL altetr 'n.t I eec troyLe IiindIing, 
(aurnann e t. , 1917) , tnon gly SUggesL that p1rolaL, (L(s noL pl ay a 
impor ant osmoregulatnry rol in humans. 
-j 0­
lable I (A Ltxii ( hara('rLstc,. of PaLlenL uith 1 Liit(air; inors 
P'atient Age Sex AbnormaliLies 
K.S. 61 y.o. male elevated pro]ictin 
of thyrotropLn 
and t-subunit 
L.0. 25 y.o female amenorrhea, ,abictorrhea, primary 
hypothyroidism (but chronically 
euthyroid on replacement), elevated 
thyrotropin, prolactin 
S.C. 69 y.o. female premature menopause with low gonad­
otropins; elevated prolactin without 
galactorrhea; elevated secretion 
of ct-subunit of thyrotropin-; 
hypoadrenal and hypothyroid. 
Replacement therapy with 5 mg 
prednisone, 0.15 img .- Thyroxine; 
clinically euthyroid 
M.G. 38 y.o. male acromegalic wiLh increased growth 
hormone, increa-sed prolactin,. 
increased thyrotropin, hyperthyroid 
N.F. 59 y.o. female elevated prolactLn without galac­
torrhea; suprasellar extension of 
tumor; premaLure menopaluse with low 
gonadotropi[n5 ; hypoLhyroid' wirth 
elevated LhyrotropLn 
M.it. 25 y.o. female oligouenorrhea wLLh elevated pro­
lactin; normal growth hormone and 
cortisol response to insulin toler­
ance test; normal thyrotropin response 
to thyrotropin ieleasing hormone 
ORIGINAL PAGE lb 
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)lable SLudies Ln 6 llyperprotactLnemL( 1'.iljc nts[H 
with a PigtitLary lunor 
A.
 
laticnL Basal Prolactin (ng/ml) n-,irmI1 Prolaictin (ng/nl) 
foLlow.tng 'il (200 jig iv) 
S.c. 11,900 12,300
 
N.F. 4,490 4,940
 
K.S. 4,200 4,320
 
559
 
96
 
L.O. 479 

M.C. 74 

98
M.MI. 62 

B. 
Hean Plasma Aldosterone ISE 
Following 1R1 Infusion tn the Same 6 Patients 
0 5 15 30 60
Time (min) 

mean 62.0 60.5* 61.2' 52.5* 74.2'Plasma Aldosterone (pg/ml) 
+ ISE 18.1 17.9 25.6 36.6 16
 
*not significantly dLfferent from 0 time value. 
LVITDhS T1'0 I [GURUS 
Fig. i. Serum proltcLtn, atdosterone and plasma renin activLty (mean + ISE) 
in 8 normal subjects following the administration of 200 ag thyrotropin 
releasing hormone Vv. Sub3ects-were supine until 60 minutes after thyrotropin 
releasing hormone injection.
 
Fig. 2. Serum prolactin and aldosterone (mean + i%) in 9 hypothyroid women
 
following the administration of 200 pg thyrotropin releasing hormone i.v.
 
The prolactin response of the normal subjects is shown on this figure as the 
shaded area. 
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